4 results match your criteria: "Amsterdam University Medical Centres - loc. AMC[Affiliation]"
A BEAT-PCD consensus statement: a core outcome set for pulmonary disease interventions in primary ciliary dyskinesia.
ERJ Open Res
January 2024
Dept of Paediatric Respiratory Medicine and Allergy, Emma Children's Hospital, Amsterdam University Medical Centres, Amsterdam, The Netherlands.
Background: Consistent use of reliable and clinically appropriate outcome measures is a priority for clinical trials, with clear definitions to allow comparability. We aimed to develop a core outcome set (COS) for pulmonary disease interventions in primary ciliary dyskinesia (PCD).
Methods: A multidisciplinary international PCD expert panel was set up.
Epigenome-Wide Association Studies of the Fractional Exhaled Nitric Oxide and Bronchodilator Drug Response in Moderate-to-Severe Pediatric Asthma.
Biomedicines
February 2023
Genomics and Health Group, Department of Biochemistry, Microbiology, Cell Biology, and Genetics, Universidad de La Laguna (ULL), 38200 San Cristóbal de La Laguna, Spain.
Article Synopsis
- * Researchers analyzed blood samples from 121 children with moderate-to-severe asthma to find DNAm markers linked to BDR and FeNO, using regression models to ensure accuracy while controlling for variables like age and sex.
- * They identified specific DNA markers and differential regions related to FeNO and BDR, with findings indicating associations with allergic reactions and inflammation, potentially opening avenues for better understanding and management of asthma in pediatric patients.
Real-life efficacy and safety of elexacaftor/tezacaftor/ivacaftor on severe cystic fibrosis lung disease patients.
Pharmacol Res Perspect
December 2022
Department of Respiratory Medicine, Amsterdam University Medical Centres - loc. AMC, Amsterdam, The Netherlands.
Article Synopsis
- Elexacaftor/tezacaftor/ivacaftor (ETI) is effective in treating cystic fibrosis patients with specific genetic mutations, showing positive results in a real-life study with Dutch patients.
- The study tracked lung function (FEV), body mass index (BMI), and adverse events over 12 months, with significant improvements observed after starting ETI.
- The treatment was well tolerated, resulting in increased lung function and BMI, fewer exacerbations, and only mild side effects such as rash and stomach aches.
Targeted exhaled breath analysis for detection of Pseudomonas aeruginosa in cystic fibrosis patients.
J Cyst Fibros
January 2022
Department Respiratory Medicine, Amsterdam University Medical Centres - loc. AMC, University of Amsterdam, Amsterdam, Netherlands; Department Paediatric Respiratory Medicine and Allergy, Emma Children's Hospital, Amsterdam University Medical Centres, Amsterdam, the Netherlands. Electronic address:
Background: Pseudomonas aeruginosa (PA) is an important respiratory pathogen for cystic fibrosis (CF) patients. Routine microbiology surveillance is time-consuming, and is best performed on expectorated sputum. As alternative, volatile organic compounds (VOCs) may be indicative of PA colonisation.
View Article and Find Full Text PDF